Image pharmaphorum Editor Views & Analysis Assessing provider (and patient) motivation Behavioural science provides a roadmap to understanding how HCPs make decisions and what drives prescribing behaviour, but also, more importantly, it gives us strategies that we can apply t Views & Analysis How can biotechnology, pharmaceutical and medical device com... By Carlos Casanova Views & Analysis The Japanese healthcare revolution Something that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and visitors alike. Events Partner Content 9th EPP Life Sciences Pricing Forum Date: October 14-16 Location: Munich ,Germany Load more results
Views & Analysis Assessing provider (and patient) motivation Behavioural science provides a roadmap to understanding how HCPs make decisions and what drives prescribing behaviour, but also, more importantly, it gives us strategies that we can apply t
Views & Analysis The Japanese healthcare revolution Something that always strikes me when visiting Japan is the uber-modern infrastructure and services enjoyed by residents and visitors alike.
Events Partner Content 9th EPP Life Sciences Pricing Forum Date: October 14-16 Location: Munich ,Germany
News EU clears first drug therapy for rare disease cALD Neuraxpharm and Minoryx' Nezglyal has become the first approved drug therapy in the EU for rare neurodegenerative disease cALD.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
